Evidence map›Paper›PMID 37292378›Full record

ArticleFrontiers in pediatrics2023

Multisystem inflammatory syndrome in children during the COVID-19 waves: data from the Juvenile Inflammatory Rheumatism cohort.

Robin Kechiche, Charlotte Borocco, Fanny Bajolle, Alexandre Belot, Sylvaine Poignant, Noémie Lachaume, Lucas Percheron, Ulrich Meinzer, Clara Mertes, Véronique Despert and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pediatrics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Observational
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 12 institutions in 1 country.

Robin KechicheDepartment of Pediatric Rheumatology, Reference Centre for Autoinflammatory Diseases and Amyloidosis (CEREMAIA), Bicêtre University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris-Saclay University, Le Kremlin-Bicêtre, France.
Charlotte BoroccoDepartment of Pediatric Rheumatology, Reference Centre for Autoinflammatory Diseases and Amyloidosis (CEREMAIA), Bicêtre University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris-Saclay University, Le Kremlin-Bicêtre, France.
Fanny BajolleDepartment of Pediatric Cardiology, M3C-Necker, Necker-Enfants Malades Hospital, AP-HP, Paris Cité University, Paris, France.
Alexandre BelotDepartment of Pediatric Nephrology, Rheumatology, Dermatology, Reference Centre of Inflammatory Rheumatism and Rare Autoimmune Diseases in Children (RAISE), Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon, Bron, France.
Sylvaine PoignantDepartment of Pediatrics, Nantes University Hospital, Nantes, France.
Noémie LachaumeDepartment of Pediatrics, Louis Mourier University Hospital, AP-HP, Paris-Cité University, Colombe, France.
Lucas PercheronPediatrics-Nephrology, Internal Medicine and Hypertension, Children Hospital-Toulouse University Hospital, Toulouse, France.
Ulrich MeinzerDepartment of General Pediatrics, Pediatric Rheumatology and Infectious Diseases, National Reference Centre for Rare Pediatric Inflammatory Rheumatisms and Systemic Autoimmune Diseases (RAISE), Robert Debré University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.
Clara MertesDepartment of Pediatrics, Strasbourg University Hospital, Strasbourg, France.
Véronique DespertDepartment of Pediatrics, Rennes University Hospital, Rennes, France.
Luc MorinPediatric Intensive Care Unit, Bicêtre University Hospital, AP-HP, Paris-Saclay University, Le Kremlin-Bicêtre, France.
Virginie LambertDepartment of Pediatric Radiology, Bicêtre University Hospital, AP-HP, Paris-Saclay University, Le Kremlin-Bicêtre, France.
Perrine DusserDepartment of Pediatric Rheumatology, Reference Centre for Autoinflammatory Diseases and Amyloidosis (CEREMAIA), Bicêtre University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris-Saclay University, Le Kremlin-Bicêtre, France.
Nassima MatsaDepartment of Pediatric Rheumatology, Reference Centre for Autoinflammatory Diseases and Amyloidosis (CEREMAIA), Bicêtre University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris-Saclay University, Le Kremlin-Bicêtre, France.
Véronique HentgenDepartment of Pediatrics, Reference Centre for Autoinflammatory Diseases and Amyloidosis (CEREMAIA), Versailles Hospital, Versailles, France.
Isabelle Kone-PautDepartment of Pediatric Rheumatology, Reference Centre for Autoinflammatory Diseases and Amyloidosis (CEREMAIA), Bicêtre University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris-Saclay University, Le Kremlin-Bicêtre, France.
Caroline GaleottiDepartment of Pediatric Rheumatology, Reference Centre for Autoinflammatory Diseases and Amyloidosis (CEREMAIA), Bicêtre University Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris-Saclay University, Le Kremlin-Bicêtre, France.
Bicêtre Hospital · FRUniversité Paris-Saclay · FRAssistance Publique – Hôpitaux de Paris · FRCentre de Recherche sur l'Inflammation · FRCentre de Référence des Maladies Autoinflammatoires et des Amyloses · FRCentre Hospitalier Universitaire de Rennes · FRCentre Hospitalier Universitaire de Toulouse · FRGénétique Médicale & Génomique Fonctionelle · FRHôpital Louis-Mourier · FRHospices Civils de Lyon · FRSorbonne Université · FRUniversité de Strasbourg · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Multisystem inflammatory syndrome in children (MIS-C) is a new condition that first appeared in children and adolescents during the COVID-19 pandemic. We aimed to describe the diagnostic course, clinical and biological manifestations, and treatment of MIS-C during the first three COVID-19 waves. Methods: We extracted patient data from the Juvenile Inflammatory Rheumatism (JIR) cohort. We analyzed data for patients meeting the World Health Organization diagnostic criteria for MIS-C from the start of the COVID-19 pandemic from March 2020 to June 30, 2021. We then compared data for patients in wave one to those in waves two and three. Results: We identified 136 patients with MIS-C. The median age decreased but not significantly during the waves, from 9.9 years to 7.3 years ( Conclusion: Over the three COVID-19 waves, with a change in the management of MIS-C, children in the JIR cohort in France showed a less severe disease course, in particular, a greater use of corticosteroids. This observation may reflect the impact of both improved management and different SARS-CoV-2 variant.

Indexed as

COVID-19epidemiologymultisystem inflammatory syndrome in childrenmyocarditiswaves of COVID-19

Identifiers

PMID37292378
PMCPMC10246474
OpenAlexW4378234934

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.